DBV loses regulatory, R&D executives ahead of peanut drug refile

DBV COO Charles Ruban and CDO Laurent Martin. (DBV Technologies)

Two of the leaders responsible for regulatory and product development at DBV Technologies are set to leave the company this month. The departures deprive DBV of senior members of its regulatory team as it gears up to refile for FDA approval of its peanut allergy drug.

COO Charles Ruban and CDO Laurent Martin are both set to leave their positions at the end of next week, although Martin will remain as DBV’s responsible pharmacist for the purposes of French rules until a replacement is found. DBV said Ruban is leaving to pursue new opportunities but offered no explanation for Martin’s departure.

Both men were central to the development of Viaskin Peanut and its submission to FDA. Ruban’s role gave him oversight of areas including regulatory and product development. Martin worked on the same areas as chief development officer.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

DBV framed the changes as a way to “flatten the organizational structure” in support of its planned evolution into a commercial-stage company. For that evolution to happen, DBV needs to persuade FDA to approve its peanut allergy drug.

Viaskin Peanut has hit bumps in the road on its path to market, from its inability to hit the primary endpoint in phase 3 through to DBV’s need to pull the original filing after the FDA identified gaps in the manufacturing and quality control sections. Three of the people involved in those events, Ruban, Martin and former CMO Lucia Septién-Velez, have left DBV this year. 

DBV is yet to replace any of the departing executives, although it did hire ex-Alexion Pharmaceuticals EVP Julie O’Neill to direct “all product development, manufacturing, supply chain, quality assurance and end-to-end process optimization” at the start of the year. O’Neill will take on Martin’s primary responsibilities.

Given the mess DBV made of the original filing, the overhaul of the regulatory leadership could be seen as a positive. But it leaves DBV without the experience of several people who were central to the development of Viaskin Peanut and with unfilled gaps in its leadership team. 

DBV needs the new-look team to nail the filing this time around. With DBV planning to refile for FDA approval months before its money runs out in the fourth quarter, there is little margin for error, particularly as the earlier setbacks have diminished its ability to raise more cash.

Shares in DBV have risen by more than 60% since the stock cratered following the filing withdrawal late last year but remain well down on the heights they scaled before the clinical and regulatory setbacks. 

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech.